Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Gruber Dafna reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Dafna Gruber received an equity award of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, each settling into one ordinary share, bringing her directly held position to 43,109 ordinary shares.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Baudot-Trajtenberg Nadine reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Nadine Baudot-Trajtenberg received an equity award of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, with each RSU settling into one Ordinary Share upon vesting. Following this award, she holds 50,744 Ordinary Shares directly.
Cellebrite DI Ltd. (CLBT) clarifies the equity dilution figures referenced in its 2026 annual meeting proxy materials. As of August 1, 2026, 251,341,060 ordinary shares were outstanding and 25,554,161 ordinary shares were reserved for issuance under the company’s equity compensation plans.
The reserved amount includes awards outstanding and shares available for future grants under the 2021 Share Incentive Plan and the Employee Share Purchase Plan, after a 3,500,000-share reduction in the 2021 plan reserve approved on July 29, 2026. On a fully diluted share count of 276,895,221, the company states that the resulting potential dilution was approximately 9.2%.
Cellebrite DI Ltd. (CLBT) reported that advisor Thomas E. Hogan sold ordinary shares in a Form 4 filing. On August 25, 2026, he sold 25,299 ordinary shares at a weighted average price of $11.2934 per share in open-market or private transactions, at prices ranging from $11.205 to $11.36. The filing states these shares had been granted as restricted stock units (RSUs) on February 10, 2026 and that the disposition was associated with the reporting person’s tax obligations arising from RSU vesting. Following the sale, Hogan directly held 765,249 ordinary shares of Cellebrite.
Cellebrite DI Ltd. (CLBT) reported that Chief Marketing Officer David Nicholas Gee sold ordinary shares in a scheduled transaction. On August 24, 2026, he sold 4,323 shares of ordinary shares at a weighted average price of $11.3605 per share, with individual trade prices ranging from $11.06 to $11.76. The sale was effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, and Gee now directly holds 135,281 shares of Cellebrite stock.
Cellebrite DI Ltd. (CLBT) is the issuer of common stock that David Gee, identified as an officer, plans to sell under Rule 144. The notice covers a proposed sale of 4,323 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate market value of $47,769.15 as of August 24, 2026. The securities to be sold arise from Restricted Stock Units from the issuer. The filing also lists prior sales by David Gee over the past three months.
Cellebrite DI Ltd. (CLBT) reported that Global Chief Revenue Officer Marcus Jewell sold 12,562 ordinary shares on August 21, 2026. The transaction was executed at a weighted average price of $11.2416 per share, from multiple trades between $11.16 and $11.30. According to the disclosure, these shares were originally granted as restricted stock units on November 15, 2023, and the disposition is associated with Jewell’s tax obligations related to RSU vesting. Following the sale, he directly holds 427,128 ordinary shares of Cellebrite.
Cellebrite DI Ltd. (CLBT) reported that Chief Marketing Officer David Nicholas Gee sold 2,198 ordinary shares on August 21, 2026 in an open-market transaction at a weighted average price of $11.2416 per share, with individual trades ranging from $11.16 to $11.30. The shares sold were originally granted as restricted stock units (RSUs) on May 20, 2024, and the disposition is associated with the reporting person’s tax obligations upon vesting of those RSUs. Following this transaction, Gee directly holds 139,604 ordinary shares of Cellebrite DI Ltd.
Cellebrite DI Ltd. (CLBT) is the issuer for which Thomas E. Hogan has filed a Rule 144 notice covering ordinary shares, par value NIS 0.00001 per share, listed on Nasdaq. The shares relate to restricted share units vested under an issuer S-8 registered compensation plan.
The reporting person states an intention to sell shares on 08/25/2026 through Morgan Stanley Smith Barney LLC under a mandatory, non-discretionary sell-to-cover arrangement solely to satisfy income tax liabilities from RSU vesting. Recent activity includes open-market sales of Cellebrite ordinary shares during the past three months.
Cellebrite DI Ltd. (CLBT) was notified that officer David Nicholas Gee filed to sell 5,673 ordinary shares of the company under Rule 144. The shares relate to restricted share units vesting under an S-8 registered compensation plan, and the filing states the sale on 08/21/2026 will be a mandatory, non-discretionary sell-to-cover transaction to satisfy income tax liabilities from vesting of performance share unit awards only. The notice also lists prior small Rule 144 sales over the past three months.